These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1285 related articles for article (PubMed ID: 21307846)

  • 1. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
    Bergamaschi MM; Queiroz RH; Chagas MH; de Oliveira DC; De Martinis BS; Kapczinski F; Quevedo J; Roesler R; Schröder N; Nardi AE; Martín-Santos R; Hallak JE; Zuardi AW; Crippa JA
    Neuropsychopharmacology; 2011 May; 36(6):1219-26. PubMed ID: 21307846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test.
    Linares IM; Zuardi AW; Pereira LC; Queiroz RH; Mechoulam R; Guimarães FS; Crippa JA
    Braz J Psychiatry; 2019; 41(1):9-14. PubMed ID: 30328956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.
    de Faria SM; de Morais Fabrício D; Tumas V; Castro PC; Ponti MA; Hallak JE; Zuardi AW; Crippa JAS; Chagas MHN
    J Psychopharmacol; 2020 Feb; 34(2):189-196. PubMed ID: 31909680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.
    Appiah-Kusi E; Petros N; Wilson R; Colizzi M; Bossong MG; Valmaggia L; Mondelli V; McGuire P; Bhattacharyya S
    Psychopharmacology (Berl); 2020 Apr; 237(4):1121-1130. PubMed ID: 31915861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
    Crippa JA; Derenusson GN; Ferrari TB; Wichert-Ana L; Duran FL; Martin-Santos R; Simões MV; Bhattacharyya S; Fusar-Poli P; Atakan Z; Santos Filho A; Freitas-Ferrari MC; McGuire PK; Zuardi AW; Busatto GF; Hallak JE
    J Psychopharmacol; 2011 Jan; 25(1):121-30. PubMed ID: 20829306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder.
    Bolsoni LM; Crippa JAS; Hallak JEC; Guimarães FS; Zuardi AW
    Psychopharmacology (Berl); 2022 May; 239(5):1499-1507. PubMed ID: 35029706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.
    Gundugurti PR; Banda N; Yadlapalli SSR; Narala A; Thatikonda R; Kocherlakota C; Kothapalli KS
    Asian J Psychiatr; 2024 Jul; 97():104073. PubMed ID: 38797087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.
    van der Flier FE; Kwee CMB; Cath DC; Batelaan NM; Groenink L; Duits P; van der Veen DC; van Balkom AJLM; Baas JMP
    BMC Psychiatry; 2019 Feb; 19(1):69. PubMed ID: 30760241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study.
    Spinella TC; Stewart SH; Naugler J; Yakovenko I; Barrett SP
    Psychopharmacology (Berl); 2021 Jul; 238(7):1965-1977. PubMed ID: 33813611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
    Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
    Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ipsapirone and cannabidiol on human experimental anxiety.
    Zuardi AW; Cosme RA; Graeff FG; Guimarães FS
    J Psychopharmacol; 1993 Jan; 7(1 Suppl):82-8. PubMed ID: 22290374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life.
    Zuardi AW; Rodrigues NP; Silva AL; Bernardo SA; Hallak JEC; Guimarães FS; Crippa JAS
    Front Pharmacol; 2017; 8():259. PubMed ID: 28553229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of Acute Agomelatine Effect in a Model of Social Anxiety in Healthy Volunteers: A Double-Blind, Placebo-Controlled Trial.
    Dos Santos RG; da Silva Dias IC; Zuardi AW; Queiroz RHC; Guimarães FS; Hallak JEC; Crippa JAS
    J Clin Psychopharmacol; 2024 Sep-Oct 01; 44(5):472-480. PubMed ID: 39008875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder.
    Adams JB; Pyke RE; Costa J; Cutler NR; Schweizer E; Wilcox CS; Wisselink PG; Greiner M; Pierce MW; Pande AC
    J Clin Psychopharmacol; 1995 Dec; 15(6):428-34. PubMed ID: 8748432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders.
    Masataka N
    Front Psychol; 2019; 10():2466. PubMed ID: 31787910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.
    Hofmann SG; Meuret AE; Smits JA; Simon NM; Pollack MH; Eisenmenger K; Shiekh M; Otto MW
    Arch Gen Psychiatry; 2006 Mar; 63(3):298-304. PubMed ID: 16520435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.
    Martin-Santos R; Crippa JA; Batalla A; Bhattacharyya S; Atakan Z; Borgwardt S; Allen P; Seal M; Langohr K; Farré M; Zuardi AW; McGuire PK
    Curr Pharm Des; 2012; 18(32):4966-79. PubMed ID: 22716148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Double-Blind, Randomized, Placebo-Controlled Test of the Effects of Cannabidiol on Experiences of Test Anxiety Among College Students.
    Stanley TB; Ferretti ML; Bonn-Miller MO; Irons JG
    Cannabis Cannabinoid Res; 2023 Dec; 8(6):1090-1099. PubMed ID: 35861792
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.
    Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL
    Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
    Schier AR; Ribeiro NP; Silva AC; Hallak JE; Crippa JA; Nardi AE; Zuardi AW
    Braz J Psychiatry; 2012 Jun; 34 Suppl 1():S104-10. PubMed ID: 22729452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.